I believe market is realizing what AGNhad in their hands. The more you read, the more you know this has more chances of working out, NP-120 is not an empty lab created drug months ago, we are talking about months/years of study and use that have proven their effects.
AGN is starting phase 2, while RVV for exemple is starting phase 3, but the risk I believe is greater with RVV...AGN has a proven and recognized drug.
It's all about that risk/return ratio, AGN's risk is lower I feel, and the return is as huge as the other Bio companies in clinical phase trials.
Good days ahead
David